



► PHARMA POOL

**Paul Biondi**  
**BRISTOL-MYERS SQUIBB APPOINTS SENIOR VP, HEAD OF BUSINESS DEVELOPMENT**



Paul Biondi

Bristol-Myers Squibb has appointed Paul Biondi as senior VP, head of business development. In this role, he is responsible for leading the development of strategic partnerships and pursuing scientific innovations across commercial, development, discovery, and technology platforms. Mr. Biondi most recently served as senior VP, head of R&D operations, at the company.

**Dr. Alan Dunton**  
**PURDUE HIRES SENIOR VP, HEAD OF R&D**



Dr. Alan Dunton

Alan Dunton, M.D., has been hired as senior VP, head of research & development at Purdue Pharma. In his new role, Dr. Dunton serves as Purdue's lead scientist, and oversees the medical research, drug safety, clinical pharmacology, virtual discovery, project management, and pharmaceuticals and analytics teams.

**Anil Kapur**  
**BAXALTA BOLSTERS ONCOLOGY UNIT**



Anil Kapur

Anil Kapur has joined Baxalta as VP and global head, oncology commercial portfolio and product strategy. Mr. Kapur joins Baxalta from J&J where he was the VP, commercial leader for the hematology franchise.

**Christeen Moburg**  
**ASTELLAS EXPANDS CORPORATE AFFAIRS**



Christeen Moburg

Astellas Pharma has named Christeen Moburg director, stakeholder engagement, within the corporate affairs team. Ms. Moburg is responsible for advancing Astellas' public policy, as well as business and reputational goals, in the U.S. and in support of the Americas. Most recently, she was alliance and advocacy director, U.S. corporate affairs oncology and infectious disease, at MedImmune.

**Vic Noble**  
**Dr. Debra Schaumberg**  
**Dr. Beth Schultz Scott**  
**SHIRE BUILDS UP ITS OPHTHALMICS TEAM**

Shire continues to expand its ophthalmics team



Vic Noble

with the appointments of Vic Noble as head of marketing, and Debra Schaumberg, OD, and Beth Schultz Scott, OD, as global medical leads.



Dr. Schaumberg

Ms. Noble joined Shire in April 2008 and in her current role, she leads all marketing activities related to Shire's ophthalmics portfolio, including its investigational candidate for dry eye disease, lifitegrast.



Dr. Schultz Scott

Dr. Schaumberg serves as a lead for U.S. and international medical affairs activities for ophthalmics, focusing on professional education and data generation.

Dr. Schultz Scott serves as a lead for U.S. and international medical affairs activities for ophthalmics, with an emphasis on lifecycle product management.

► AGENCY POOL

**Jennifer Durante**  
**DIGITAS HEALTH LIFEBRANDS NAMES EXECUTIVE VP**



Jennifer Durante

Jennifer Durante has joined the New York account team of Digitas Health LifeBrands as its new executive VP, director of client services. She is charged with nurturing and growing the New York account team and client relationships. Most recently, Ms. Durante was executive VP, senior director at BBDO New York, working on the GE business.

**Mark Forbes Irving**  
**IDEA PHARMA NAMES MANAGING DIRECTOR**



Mark Forbes Irving

Mark Forbes Irving, who has been named managing director of IDEA Pharma, is charged with driving the next phase of the company's growth. He joins the company from Quintiles where he was director of health engagement and communications.

**Martin Mannion**  
**GUIDEMARK NAMES CHIEF STRATEGY OFFICER**

Guidemark Health has named Martin Mannion



Martin Mannion

as chief strategy officer. He is charged with expanding Guidemark Health's current brand strategy and branding discipline. Previously, he was chief strategy officer for IPG's ICC Lowe.

**Adam Persing**  
**MRB PARTNERS NAMES CHIEF DATA SCIENTIST**




Adam Persing

Medical-communications start-up MRB Partners, which was recently launched by Maureen Regan, Richard Campbell, and Brendan Ward, the team who founded Regan Campbell Ward, has named Adam Persing VP,

chief data scientist.

Mr. Persing joins the agency from Mezocliq, a New York-based software company.

**Megan Thomas**  
**MAKOVSKY SUPPORTS BIOTECH OPERATIONS WITH NEW HIRE**



Megan Thomas

Makovsky, an independent integrated communications firm, has named Megan Thomas as senior VP, health practice. She is charged with leading the agency's Cambridge, Mass., expansion.

Before joining Makovsky, Ms. Thomas was global head of communications, Sanofi Oncology.

► SERVICE POOL

**Rajeev Nair**  
**J. KNIPPER AND COMPANY APPOINTS CHIEF TECHNOLOGY OFFICER**



Rajeev Nair

J. Knipper and Company, a provider of direct marketing, sampling, compliance, information technology, and salesforce productivity solutions, has named Rajeev Nair chief technology officer to lead its development and information technology departments. Mr. Nair comes to Knipper with a wealth of experience in software development and leading large organizations in the entire software development lifecycle process. <sup>PV</sup>



FOR BONUS CONTENT  
USE YOUR QR CODE READER  
OR GO TO  
[bit.ly/PV0116-Pool](http://bit.ly/PV0116-Pool)



## ► BIOTECH POOL

### **Dr. Volker Herrmann** **VIAMET APPOINTS CHIEF** **COMMERCIAL OFFICER**

Viamet Pharmaceuticals has appointed Volker Herrmann, M.D., as chief commercial officer. Dr. Herrmann is an accomplished pharmaceutical executive with extensive experience in sales, marketing, commercial strategy, and market access. Before joining Viamet, Dr. Herrmann served as head of global strategy, commercial development and global marketing for the vaccines business unit of Pfizer Inc.

### **Dr. Jose Iglesias** **BIOHERA APPOINTS CHIEF** **MEDICAL OFFICER**

Biohera Pharmaceuticals has appointed Jose Iglesias, M.D., as chief medical officer. Dr. Iglesias is responsible for clinical development, medical affairs, and other functions related to the advancement of Imprime PGG, the company's cancer immunotherapy currently in multiple mid- and late-stage clinical testing.

Dr. Iglesias, who has 25 years of global experience in the pharmaceutical industry, was most recently chief medical officer of Bionomics, where he was responsible for the development of its clinical oncology pipeline, including antivasular agents, monoclonal antibodies, and small molecule kinase inhibitors.

### **Dr. Garry Menzel** **PRONUTRIA BIOSCIENCES APPOINTS CHIEF** **BUSINESS AND STRATEGY OFFICER**

Pronutria Biosciences, a biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, has appointed Garry Menzel, Ph.D., as chief business and strategy officer. Dr. Menzel joins Pronutria from DaVita Healthcare Partners, where he served as chief financial officer with a broad range of strategic responsibilities.

### **Adele Sommerfeld** **AVAX TECHNOLOGIES APPOINTS CEO**

AVAX Technologies, a pioneer and leader in the clinical development and production of autologous cancer immunotherapy vaccines, has named Adele Sommerfeld as CEO. Ms. Sommerfeld joins the AVAX management team with a breadth of experience within the biotechnology industry, spanning more than 25 years. She brings significant experience across functional areas including biotechnology equity financing transactions, corporate strategy, strategic partnering, and business development.

## ► BIOPHARMA POOL

### **Robert Azelby** **JUNO THERAPEUTICS APPOINTS CHIEF** **COMMERCIAL OFFICER**

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, has appointed Robert Azelby as executive VP, chief commercial officer. Before joining Juno, Mr. Azelby was at Amgen, where he was VP and general manager of Amgen's oncology business unit.

### **Dr. Miguel Barbosa** **MIRNA THERAPEUTICS APPOINTS VP AND** **CHIEF SCIENTIFIC OFFICER**

Mirna Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, has appointed Miguel Barbosa, Ph.D., as executive VP and chief scientific officer.

Most recently, Dr. Barbosa was executive in residence, therapeutic innovation at Johnson & Johnson Innovation, where he led the identification and development of new R&D and business models.

### **Dr. Xin Du** **Dr. Sri Srivastava** **ACTINIUM PHARMACEUTICALS** **STRENGTHENS PRODUCT DEVELOPMENT** **EFFORTS WITH SENIOR LEVEL HIRES**

Actinium Pharmaceuticals, a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has appointed Xin Du, Ph.D., to the position of executive director, regulatory affairs, and Sri Srivastava, Ph.D., to the position of associate director of project management.

Dr. Du is responsible for managing Actinium's regulatory submissions, CMC efforts, interacting with regulatory agencies and developing the company's regulatory strategy as pertains to both lomab-B, Actimab-A and all future programs.

Dr. Srivastava has operational responsibilities for the company's Actimab-A program, including the planned Phase II clinical trial, planning and process optimization, management of external vendors, and the coordination of all clinical-trial related matters.

### **Dr. Elizabeth Trehu** **JOUNCE THERAPEUTICS APPOINTS CHIEF** **MEDICAL OFFICER**

Jounce Therapeutics, which is focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, has appointed Elizabeth Trehu, M.D., to the po-

sition of chief medical officer. Dr. Trehu brings to Jounce more than 25 years of clinical experience, including almost 15 years in the biotech industry leading translational and integrated hematology and oncology drug development.

## ► CRO POOL

### **Kevin Gordon** **QUINTILES NAMES CHIEF** **OPERATING OFFICER**

Quintiles has promoted Kevin Gordon, who is currently serving as executive VP, operations and chief financial officer, to chief operating officer.

With this appointment, Quintiles is formalizing many of Mr. Gordon's activities with customers, its executives, and employees.

Over the years, he has increased his operational influence and is already managing a substantive amount of Quintiles' business in addition to his financial leadership of the company.

### **Dr. Gerald Messerschmidt** **ACT ONCOLOGY APPOINTS NEW CHIEF** **MEDICAL OFFICER**

ACT Oncology, an oncology specialist CRO, has appointed of Gerald Messerschmidt, M.D., as chief medical officer (CMO).


Formerly a consultant for the company, Dr. Messerschmidt is providing medical and safety leadership in addition to lending his expertise to the development of sponsors' clinical development strategies.

### **Dr. Dieter Seitz-Tutter** **SYNTERACTHCR APPOINTS VP OF GLOBAL** **CLINICAL OPERATIONS**

SynteractHCR, a full-service CRO, has named Dr. Dieter Seitz-Tutter as VP, global clinical operations. This new position was established to accommodate the continued growth of the company as SynteractHCR extends its reach supporting the drug development programs of small to mid-sized biopharma companies.

He is charged with leading the company's experienced clinical operations teams while fostering good communication between SynteractHCR, study sites, and the sponsor.

Dr. Seitz-Tutter has more than 25 years of experience in clinical research, 20 of which he spent in the CRO industry.

Most recently, he was VP of global clinical development at Chiltern where he was responsible for all clinical and country operations outside of North America. 

8th Annual

# DIGITAL PHARMA EUROPE

AstraZeneca 

1-3 March 2016 — Alderley Park, Cheshire, UK  
[www.digitalpharmaseries.com/europe](http://www.digitalpharmaseries.com/europe)

Get 15% Off Standard Registration with Discount Code PharmaVoice



5th Annual

# DIGITAL MARKETING for Medical Devices WEST

April 18-20, 2016 — San Francisco, CA  
Hyatt Fisherman's Wharf  
[www.exlevents.com/DigDevicesWest](http://www.exlevents.com/DigDevicesWest)

